Thiabendazole for the treatment of strongyloidiasis in patients with hematologic malignancies.
A total of 21 patients with hematologic malignancies were given thiabendazole for treatment of strongyloidiasis. Fifteen patients were cured. Since there were no relapses, it is unlikely that maintenance therapy has a role in the management of strongyloidiasis in this population of patients.
Schaffel
R
R
Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Brazil.
Nucci
M
M
Portugal
R
R
Castro
M B
MB
Ferreira
S B
SB
Almeida
L
L
Spector
N
N
Pulcheri
W
W
D000293:Adolescent; D000328:Adult; D000368:Aged; D000969:Antinematodal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004244:Dizziness / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D013322:Strongyloidiasis / Q000150:complications / Q000188:drug therapy*; D013827:Thiabendazole / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000969:Antinematodal Agents; D013827:Thiabendazole